Fenoldopam (SKF-82526) is a synthetic benzazepine analog acting as a selective D1 receptor partial agonist. It was approved by the Food and
Drug Administration (FDA) in September 1997 as an antihypertensive agent. Since fenoldopam is the
only intravenous agent that improves renal perfusion, in theory it could
be beneficial in hypertensive patients with concomitant renal
insufficiency.